Fund Vi, L.P.Omega Fund Vi ... Net Worth

The estimated Net Worth of Fund Vi, L.P.Omega Fund Vi ... is at least $1.02 Milion dollars as of 14 October 2020. Fund Vi owns over 250,000 units of Spruce Biosciences stock worth over $1,015,680 and over the last 4 years Fund sold SPRB stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Fund Vi SPRB stock SEC Form 4 insiders trading

Fund has made over 1 trades of the Spruce Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently Fund bought 250,000 units of SPRB stock worth $3,750,000 on 14 October 2020.

The largest trade Fund's ever made was buying 250,000 units of Spruce Biosciences stock on 14 October 2020 worth over $3,750,000. On average, Fund trades about 250,000 units every 0 days since 2020. As of 14 October 2020 Fund still owns at least 2,161,022 units of Spruce Biosciences stock.

You can see the complete history of Fund Vi stock trades at the bottom of the page.

Insiders trading at Spruce Biosciences

Over the last 4 years, insiders at Spruce Biosciences have traded over $10,017,426 worth of Spruce Biosciences stock and bought 4,788,400 units worth $38,247,728 . The most active insiders traders include Holdings A/S Novo, Bali Muralidhar a Niall O'donnell. On average, Spruce Biosciences executives and independent directors trade stock every 57 days with the average trade being worth of $210,541. The most recent stock trade was executed by Holdings A/S Novo on 21 March 2024, trading 465,021 units of SPRB stock currently worth $348,766.

What does Spruce Biosciences do?

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Complete history of Fund Vi stock trades at Spruce Biosciences

Spruce Biosciences executives and stock owners

Spruce Biosciences executives and other stock owners filed with the SEC include:

• Dr. Rosh Dias,
  Chief Medical Officer
• Samir M. Gharib CPA, CPA, M.B.A.,
  Pres & CFO
• Richard A. King M.B.A.,
  CEO & Director
• Michael G. Grey,
  Exec. Chairman
• Dr. Javier Szwarcberg M.D., M.P.H.,
  CEO & Director
• Samir M. Gharib CPA, M.B.A., CPA,
  Chief Financial Officer
• Tiba Aynechi,
  
• Michael G Grey,
  Executive Chairman
• Kirk Ways,
  
• Daniel K Spiegelman,
  
• Camilla V Simpson,
  
• Ralph William Iii Charlton,
  CHIEF MEDICAL OFFICER
• Javier B. Szwarcberg,
  CHIEF EXECUTIVE OFFICER
• Jonas Hansson,
  Director
• Viii, L.P. Health Cap,
  
• Fund Vi, L.P.Omega Fund Vi ...,
  
• Moghrabi Dina Chaya,
  Director
• Niall O'donnell,
  Director
• Bali Muralidhar,
  
• Venture Fund Iii, L.P.River...,
  
• Holdings A/S Novo,
  10% owner
• Richard King,
  Chief Executive Officer
• Subaweerage Dias,
  Chief Medical Officer
• Samir M. Gharib,
  PRESIDENT AND CFO
• Percival Barretto Ko,